 |
|
|
| |
ADDING PEGINTERFERON TO ENTECAVIR INCREASES RESPONSE RATES IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS: WEEK 96 RESULTS OF A GLOBAL MULTICENTER RANDOMISED TRIAL (ARES STUDY)
|
| |
| |
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
W.P. Brouwer1, Q. Xie2, M.J. Sonneveld1, N.P. Zhang3, Q. Zhang4, F. Tabak5, A. Streinu6, J.-Y. Wang3, R. Idilman7, H. Reesink8, M. Diculescu9, K. Simon10, M. Voiculescu11, M. Akdogan12, W. Mazur13, J.G.P Reijnders1, E. Verhey1, B.E. Hansen1,14 and H.L.A. Janssen1,15
1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 2Infectious Diseases, Ruijin Hospital, Jiaotong University, Shanghai, China; 3Gastroenterology and Hepatology, Zhong Shan Hospital, Fu Dan University, Shanghai, China; 4Gastroenterology and Hepatology, Shanghai Public Health Center, Fu Dan University, Shanghai, China; 5Cerrahpasa Medical Faculty, Istanbul, Turkey; 6National Institute of Infectious Disease, Bucharest, Romania; 7University of Ankara, Medical School, Ankara, Turkey; 8Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands; 9Department of Gastroenterology, Fundeni Clinical Institute, Bucharest, Romania; 10Division of Infectious Diseases and Hepatology, Wroclaw Medical University, Poland; 11Department of Internal Medicine, Fundeni Cinical Institute, Bucharest, Romania; 12Yuksek Ihsitas Hospital, Department of Gastroenterology, Ankara, Turkey; 13Specialistic Medical Practice, Zawiercie, Poland; 14Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 15Toronto Center for Liver Disease, Toronto Western and General Hospital, University Health Network, Toronto, Canada
|
| |
|
|
|
|
|
